Publications by authors named "Tamara Postigo"
Article Synopsis
- The review analyzed the prevalence of viraemia in infections caused by SARS-CoV-2 and other respiratory viruses, involving a systematic search of articles published before May 23, 2024.
- A total of 202 articles were studied, finding a 34% prevalence of viraemia in SARS-CoV-2 cases and a range of 6% to 65% for other viruses.
- The study highlighted that viraemia correlates with greater disease severity and can lead to long-term issues like memory problems and diminished quality of life, suggesting its significance in understanding respiratory viral infections.
Objectives: Identifying patients with COVID-19 who are at risk of poor evolution is key to early decide on their hospitalization. We evaluated the combined impact of nucleocapsid (N)-antigenemia profiled by a rapid test and antibodies against the S1 subunit of the SARS-CoV S protein (S1) on the hospitalization risk of patients with COVID-19.
Methods: N-antigenemia and anti-S1 antibodies were profiled at admission to the emergency department in 146 patients with COVID-19 using the Panbio® antigen Rapid Test and the SARS-CoV-2 immunoglobulin G II Quant/SARS-CoV-2 immunoglobulin G assay from Abbott.
Background: The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU.
View Article and Find Full Text PDFObjectives: To evaluate if the detection of N antigen of SARS-CoV-2 in plasma by a rapid lateral flow test predicts 90-day mortality in COVID-19 patients hospitalized at the wards.
Methods: The presence of N-antigenemia was evaluated in the first 36 hours after hospitalization in 600 unvaccinated COVID-19 patients, by using the Panbio COVID-19 Ag Rapid Test Device from Abbott (Abbott Laboratories Inc., Chicago, IL, USA).